Trial reportJournal of cosmetic dermatology2026
Effectiveness, Tolerability, and Acceptance of a Food Supplement in the Management of Non-Illness-Related Hair Loss and Thinning.
Trial report in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundDiffuse hair loss and shedding is often managed with food supplements, yet evidence for ingredient combinations is limited. Our exploratory study evaluated a nutritional supplement (Priorin capsules, Bayer) containing millet extract, pantothenic acid (vitamin B5), L-cystine, and biotin (vitamin B7) in healthy subjects with light diffuse hair loss.
methodsIn this open-label, intra-individual, multicenter study, subjects with non-illness-related, light diffuse hair loss used the product (two capsules/day) for 12 weeks. Endpoints included objective measurements of hair density, hair growth coefficient, and hair loss (phototrichogram), subjective evaluations of hair appearance, beauty and volume (hairdresser-rated), consumer perception and acceptance, and tolerability.
resultsIn 112 subjects (mean age 32 ± 1 years; 93.8% female), hair density (n = 109) and the proportion of hairs in the anagen phase increased significantly, while the telogen proportion decreased (p < 0.001, week 12 vs. baseline). Hair loss had declined by 59% at week 12 (p < 0.001). Significant improvements in the hairdresser-rated hair quality and appearance parameters (shine, softness/elasticity, strength, smoothness, dryness, vitality, volume) were observed (p < 0.001). From week 2, subjects reported progressive improvement in appearance, growth, and slowing of hair loss. At week 12, 90% of subjects perceived improved hair appearance and growth, 85% reported slowing down of hair loss, and 82% were satisfied with the overall hair improvements with treatment. The supplement was generally well tolerated.
conclusionsThe combination of millet extract, pantothenic acid, L-cystine, and biotin was associated with reduced hair loss, improvements in hair growth and appearance, and high subject satisfaction, and was well tolerated over 12 weeks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.